Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT06764706 · clinicaltrials.gov ↗
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie